Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting

Rhea-AI Filing Summary

Mineralys Therapeutics reported proposed sales of Common Stock by an affiliate under a Form 144 notice. The filing lists prior transfers of 75,000 shares on 03/31/2026 for $1,970,520.69 and 15,730 shares on 04/13/2026 for $421,979.55. The excerpt also lists scheduled vesting of restricted share unit awards on 07/10/2024, 10/10/2024, and 01/10/2025 for 24,619, 35,954, and 14,427 shares respectively.

Insights

Securities Compliance Counsel

Form 144 discloses proposed or recent sales by an affiliate; filings are procedural notices.

Form 144 provides a statutory notice of proposed sales of restricted or control securities. The listing here shows executed transfers dated 03/31/2026 and 04/13/2026 with exact share counts and proceeds recorded.

These notices do not by themselves explain trading motive or venue. Subsequent public filings or broker records would show whether further sales occur; timing and cash‑flow treatment are not stated in the excerpt.

Key Figures

Shares sold on 03/31/2026: 75,000 shares Proceeds for 03/31/2026 transfer: $1,970,520.69 Shares sold on 04/13/2026: 15,730 shares +4 more

7 metrics

Shares sold on 03/31/2026 75,000 shares transfer dated 03/31/2026 recorded in Form 144

Proceeds for 03/31/2026 transfer $1,970,520.69 dollar amount shown alongside 75,000 shares

Shares sold on 04/13/2026 15,730 shares transfer dated 04/13/2026 recorded in Form 144

Proceeds for 04/13/2026 transfer $421,979.55 dollar amount shown alongside 15,730 shares

RSU vesting 07/10/2024 24,619 shares Vesting of restricted share unit award on 07/10/2024

RSU vesting 10/10/2024 35,954 shares Vesting of restricted share unit award on 10/10/2024

RSU vesting 01/10/2025 14,427 shares Vesting of restricted share unit award on 01/10/2025

Key Terms

Form 144, restricted share unit award, Common Stock

3 terms

Form 144 regulatory

"Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted share unit award financial

"Vesting of restricted share unit award 07/10/2024"

Common Stock market

"Securities To Be Sold | Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/30/2026 - 04:20 PM Accepted by SEC EDGAR 06/30/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	75000	1960601.58	82498101	06/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/10/2024	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			24619	07/10/2024	Granted as part of issuer equity compensation plan
Common Stock	10/10/2024	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			35954	10/10/2024	Granted as part of issuer equity compensation plan
Common Stock	01/10/2025	Vesting of restricted share unit award	Mineralys Therapeutics, Inc.			14427	01/10/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	03/31/2026	75000	1970520.69
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/13/2026	15730	421979.55

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mineralys Therapeutics' Form 144 show about insider sales?

The Form 144 lists prior transfers of Common Stock totaling 90,730 shares. It records 75,000 shares on 03/31/2026 for $1,970,520.69 and 15,730 shares on 04/13/2026 for $421,979.55, reported as past transfers in the filing.

Who is the reporting party on the Mineralys Therapeutics Form 144?

The filing names Jon Congleton at the Radnor PA address. The document associates the listed Common Stock transfers and the Form 144 notice with that reporting address and name shown in the excerpt.

Does the Form 144 show RSU vesting for Mineralys Therapeutics?

Yes. The excerpt lists scheduled RSU vesting dates and amounts. It shows vesting of 24,619 shares on 07/10/2024, 35,954 shares on 10/10/2024, and 14,427 shares on 01/10/2025 as granted under the issuer equity compensation plan.

Are the proceeds recipients or use of proceeds disclosed?

The excerpt records dollar amounts for specific share transfers but does not state proceeds recipients or use of proceeds. The filing shows sale amounts tied to the transfer dates but provides no further cash‑flow attribution in the provided text.